Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients

Diabetes Research and Clinical Practice

Volumn 76, Issue 3, 2007, Pages 358-367

  Yoshikawa, Ritsuko ^a   Wada, Jun ^a   Seiki, Kousuke ^b   Matsuoka, Takashi ^c   Miyamoto, Satoshi ^d   Takahashi, Kenji ^d   Ota, Sachiko ^e   Taniai, Kazuhi ^e   Hida, Kazuyuki ^f   Yamakado, Minoru ^g   Shikata, Kenichi ^a   Uehara, Yoshio ^h   Urade, Yoshihiro ⁱ   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Maruha Nichiro Holdings Inc   (Japan)

^c Kurashiki Life Style Disease Center   (Japan)

^d KURASHIKI CENTRAL HOSPITAL   (Japan)

^e Okayama Central Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^g MITSUI MEMORIAL HOSPITAL   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ OSAKA BIOSCIENCE INSTITUTE   (Japan)

Author keywords

Atherosclerosis; Cardiovascular disease; Metabolic syndrome; Microalbuminuria; Type 2 diabetes

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; COLLAGEN TYPE 4; N ACETYL BETA GLUCOSAMINIDASE; PROSTAGLANDIN D SYNTHASE;

ADULT; ARTICLE; BETA 2 MICROGLOBULIN URINE LEVEL; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INDEPENDENT VARIABLE; JAPANESE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PROTEIN URINE LEVEL; RISK; STROKE; WORLD HEALTH ORGANIZATION;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CEREBRAL ARTERIAL DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 33947607351     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.09.004     Document Type: Article

References (38)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 12 (1988) 1595-1607
2. Kaplan N.M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch. Intern. Med. 149 7 (1989) 1514-1520
3. DeFronzo R.A., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diab. Care 14 3 (1991) 173-194
4. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab. Med. 15 7 (1998) 539-553
5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA 285 (19) (2001) 2486-2497.
6. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286 4 (2001) 421-426
7. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 14 (2002) 1777-1782
8. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., Schroll M., and Jensen J.S. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arteriosc. Thromb. Vasc. Biol. 19 8 (1999) 1992-1997
9. Roest M., Banga J.D., Janssen W.M., Grobbee D.E., Sixma J.J., de Jong P.E., et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 103 25 (2001) 3057-3061
10. Urade Y., and Hayaishi O. Prostaglandin D synthase: structure and function. Vit. Horm. 58 (2000) 89-120
11. Urade Y., Watanabe K., and Hayaishi O. Prostaglandin D, E, and F synthases. J. Lipid Mediat. Cell Signal 12 2/3 (1995) 257-273
12. Hirawa N., Uehara Y., Ikeda T., Gomi T., Hamano K., Totsuka Y., et al. Urinary prostaglandin D synthase (beta-trace) excretion increases in the early stage of diabetes mellitus. Nephron 87 4 (2001) 321-327
13. Hamano K., Totsuka Y., Ajima M., Gomi T., Ikeda T., Hirawa N., et al. Blood sugar control reverses the increase in urinary excretion of prostaglandin D synthase in diabetic patients. Nephron 92 1 (2002) 77-85
14. Meigs J.B., Wilson P.W., Nathan D.M., D'Agostino Sr. R.B., Williams K., and Haffner S.M. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52 8 (2003) 2160-2167
15. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care 24 4 (2001) 683-689
16. Bonora E., Targher G., Formentini G., Calcaterra F., Lombardi S., Marini F., et al. The metabolic syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diab. Med. 21 1 (2004) 52-58
17. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M.R., and Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44 9 (2001) 1148-1154
18. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., and Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med. 164 10 (2004) 1066-1076
19. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 10 (2004) 1245-1250
20. Hunt K.J., Resendez R.G., Williams K., Haffner S.M., and Stern M.P. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110 10 (2004) 1251-1257
21. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., and Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109 1 (2004) 42-46
22. Alexander C.M., Landsman P.B., Teutsch S.M., and Haffner S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 5 (2003) 1210-1214
23. Oda H., Shiina Y., Seiki K., Sato N., Eguchi N., and Urade Y. Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin. Chem. 48 9 (2002) 1445-1453
24. Kwon H.M., Kim B.J., Lee S.H., Choi S.H., Oh B.H., and Yoon B.W. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 37 2 (2006) 466-470
25. Vermeer S.E., Hollander M., van Dijk E.J., Hofman A., Koudstaal P.J., and Breteler M.M. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34 5 (2003) 1126-1129
26. Lempiainen P., Mykkanen L., Pyorala K., Laakso M., and Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 100 2 (1999) 123-128
27. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 21 (2002) 2709-2716
28. Ford E.S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diab. Care 28 11 (2005) 2745-2749
29. Matsumoto K., Miyake S., Yano M., Ueki Y., Yamaguchi Y., Akazawa S., et al. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diab. Care 20 10 (1997) 1562-1568
30. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 4 (2004) 380-385
31. Thomas G.N., Lin J.W., Lam W.W., Tomlinson B., Yeung V., Chan J.C., et al. Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in type 2 diabetic Chinese patients. Diabetologia 47 9 (2004) 1528-1534
32. Yokoyama H., Aoki T., Imahori M., and Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 66 1 (2004) 448-454
33. Yuyun M.F., Khaw K.T., Luben R., Welch A., Bingham S., Day N.E., et al. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J. Intern. Med. 255 2 (2004) 247-256
34. Martinez-Vea A., Salvado E., Bardaji A., Gutierrez C., Ramos A., Garcia C., et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am. J. Kidney Dis. 47 2 (2006) 241-250
35. Kobayashi S., Ikeda T., Moriya H., Ohtake T., and Kumagai H. Asymptomatic cerebral lacunae in patients with chronic kidney disease. Am. J. Kidney Dis. 44 1 (2004) 35-41
36. Hong C.Y., Chia K.S., and Ling S.L. Urinary protein excretion in type 2 diabetes with complications. J. Diab. Complications 14 5 (2000) 259-265
37. Weitgasser R., Schnoell F., Gappmayer B., and Kartnig I. Prospective evaluation of urinary N-acetyl-beta-d-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diab. Care 22 11 (1999) 1882-1886
38. Eguchi Y., Eguchi N., Oda H., Seiki K., Kijima Y., Matsu-ura Y., et al. Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc. Natl. Acad. Sci. USA 94 26 (1997) 14689-14694